WO2012074842A3 - Compositions and methods for treating neoplasia - Google Patents

Compositions and methods for treating neoplasia Download PDF

Info

Publication number
WO2012074842A3
WO2012074842A3 PCT/US2011/061872 US2011061872W WO2012074842A3 WO 2012074842 A3 WO2012074842 A3 WO 2012074842A3 US 2011061872 W US2011061872 W US 2011061872W WO 2012074842 A3 WO2012074842 A3 WO 2012074842A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating neoplasia
treating
tslp
Prior art date
Application number
PCT/US2011/061872
Other languages
French (fr)
Other versions
WO2012074842A2 (en
Inventor
Arya Biragyn
Warren J. Leonard
Original Assignee
The United States Of America, As Represented By The Secretary, National Institute Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, National Institute Of Health filed Critical The United States Of America, As Represented By The Secretary, National Institute Of Health
Publication of WO2012074842A2 publication Critical patent/WO2012074842A2/en
Publication of WO2012074842A3 publication Critical patent/WO2012074842A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

The invention features compositions comprising agent that inhibits thymic stromal lymphopoietin (TSLP) or TSLP Receptor expression or biological activity, and related methods of using the compositions for treating or preventing cancer progression or metastasis.
PCT/US2011/061872 2010-11-23 2011-11-22 Compositions and methods for treating neoplasia WO2012074842A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41661910P 2010-11-23 2010-11-23
US61/416,619 2010-11-23

Publications (2)

Publication Number Publication Date
WO2012074842A2 WO2012074842A2 (en) 2012-06-07
WO2012074842A3 true WO2012074842A3 (en) 2013-04-04

Family

ID=46172472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061872 WO2012074842A2 (en) 2010-11-23 2011-11-22 Compositions and methods for treating neoplasia

Country Status (1)

Country Link
WO (1) WO2012074842A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015187519A1 (en) * 2014-06-06 2015-12-10 Merck Sharp & Dohme Corp. Tslp assay
EA036833B1 (en) 2014-09-10 2020-12-24 Вашингтон Юниверсити Method of treating precancerous skin lesions
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
LT3347377T (en) 2015-09-09 2021-05-25 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010086445A1 (en) * 2009-01-30 2010-08-05 Institut Curie Tslp promotes immune evasion and persistence of viruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010086445A1 (en) * 2009-01-30 2010-08-05 Institut Curie Tslp promotes immune evasion and persistence of viruses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALEXANDER PEDROZA-GONZALEZ ET AL.: "Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation", J. EXP. MED., vol. 208, no. 3, 21 February 2011 (2011-02-21), pages 479 - 490 *
PUREVDORJ B. OLKHANUD ET AL.: "Thymic stromal lymphopoietin is a key mediator of breast cancer progression", THE JOURNAL OF IMMUNOLOGY, vol. 186, no. 10, 13 April 2011 (2011-04-13), pages 5656 - 5662 *
VALERIE I. BROWN ET AL.: "Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7R a signaling", CANCER RESEARCH, vol. 67, no. 20, 2007, pages 9963 - 9970 *

Also Published As

Publication number Publication date
WO2012074842A2 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
PH12020550450A1 (en) Certain chemical entities, compositions and methods
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
MX2009008430A (en) Anti-robo4 antibodies and uses therefor.
NZ702195A (en) Anti-ly6e antibodies and immunoconjugates and methods of use
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MX336001B (en) Anti-axl antibodies and methods of use.
PH12017500864A1 (en) Anti-notch1 antibodies
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
MX356282B (en) Compositions and methods comprising protease variants.
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2011034947A3 (en) Reagents and methods for modulating cone photoreceptor activity
WO2010120757A3 (en) Regeneration of tissue without cell transplantation
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
MX340555B (en) Antibodies against il-18r1 and uses thereof.
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
WO2012058241A3 (en) Methods and compositions for ameliorating pancreatic cancer
MX2011010012A (en) Novel anti-î+-5î²1 antibodies and uses thereof.
WO2011060363A3 (en) Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2010144477A3 (en) Sulfonylurea modulators of endothelin receptor
MX2012011829A (en) Anti-polyubiquitin antibodies and methods of use.
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
MX2013007230A (en) Polymer systems.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11844044

Country of ref document: EP

Kind code of ref document: A2